LB Pharmaceuticals reports Q3 2026 results, affirms 1H 2027 data for schizophrenia drug
The company said enrollment in its Phase 3 NOVA-2 trial of LB-102 is progressing and topline data remain on track for the first half of 2027, with cash expected to last beyond the second quarter of 2029.
SEC filing